Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital

Andrew W. Walter, Raymond K. Mulhern, Amar Gajjar, Richard L. Heideman, David Reardon, R. Alex Sanford, Xiaoping Xiong, Larry E. Kun

Research output: Contribution to journalArticle

170 Citations (Scopus)

Abstract

Purpose: Young children treated for medulloblastoma are at especially high risk for morbidity and mortality from their disease and therapy. This study sought to assess the relationship, if any, between patient outcome and M stage. Neuropsychologic and endocrine outcomes were also assessed. Patients and Methods: Twenty-nine consecutively diagnosed infants and young children were treated for medulloblastoma at St Jude Children's Research Hospital between November 1984 and December 1995. All patients were treated with the intent of using postoperative chemotherapy to delay planned irradiation. Results: The median age at diagnosis was 2.6 years. Six patients completed planned chemotherapy without progressive disease and underwent irradiation at completion of chemotherapy. Twenty-three children experienced disease progression during chemotherapy and underwent irradiation at the time of progression. The 5-year overall survival rate for the entire cohort was 51% ± 10%. The 5-year progression-free survival rate was 21% ± 8%. M stage did not impact survival. All patients lost cognitive function during and after therapy at a rate of -3.9 intelligence quotient points per year (P = .0028). Sensory functions declined significantly after therapy (P = .007). All long- term survivors required hormone replacement therapy and had growth abnormalities. Conclusion: The majority of infants treated for medullablastoma experienced disease progression during initial chemotherapy. However, more than half of these patients can be cured with salvage radiation therapy, regardless of M stage. The presence of metastatic disease did not increase the risk of dying from medullablastoma. All patients treated in this fashion have significant neuropsychologic deficits. Our experience demonstrates that medulloblastoma in infancy is a curable disease, albeit at a significant cost.

Original languageEnglish (US)
Pages (from-to)3720-3728
Number of pages9
JournalJournal of Clinical Oncology
Volume17
Issue number12
DOIs
StatePublished - Jan 1 1999

Fingerprint

Medulloblastoma
Survival
Research
Drug Therapy
Disease Progression
Survival Rate
Salvage Therapy
Hormone Replacement Therapy
Intelligence
Cognition
Disease-Free Survival
Survivors
Radiotherapy
Therapeutics
Morbidity
Costs and Cost Analysis
Mortality
Growth

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Walter, A. W., Mulhern, R. K., Gajjar, A., Heideman, R. L., Reardon, D., Sanford, R. A., ... Kun, L. E. (1999). Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital. Journal of Clinical Oncology, 17(12), 3720-3728. https://doi.org/10.1200/JCO.1999.17.12.3720

Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital. / Walter, Andrew W.; Mulhern, Raymond K.; Gajjar, Amar; Heideman, Richard L.; Reardon, David; Sanford, R. Alex; Xiong, Xiaoping; Kun, Larry E.

In: Journal of Clinical Oncology, Vol. 17, No. 12, 01.01.1999, p. 3720-3728.

Research output: Contribution to journalArticle

Walter, AW, Mulhern, RK, Gajjar, A, Heideman, RL, Reardon, D, Sanford, RA, Xiong, X & Kun, LE 1999, 'Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital', Journal of Clinical Oncology, vol. 17, no. 12, pp. 3720-3728. https://doi.org/10.1200/JCO.1999.17.12.3720
Walter, Andrew W. ; Mulhern, Raymond K. ; Gajjar, Amar ; Heideman, Richard L. ; Reardon, David ; Sanford, R. Alex ; Xiong, Xiaoping ; Kun, Larry E. / Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital. In: Journal of Clinical Oncology. 1999 ; Vol. 17, No. 12. pp. 3720-3728.
@article{303fecc03cbc4e0aa2a10f7e0f8315bb,
title = "Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital",
abstract = "Purpose: Young children treated for medulloblastoma are at especially high risk for morbidity and mortality from their disease and therapy. This study sought to assess the relationship, if any, between patient outcome and M stage. Neuropsychologic and endocrine outcomes were also assessed. Patients and Methods: Twenty-nine consecutively diagnosed infants and young children were treated for medulloblastoma at St Jude Children's Research Hospital between November 1984 and December 1995. All patients were treated with the intent of using postoperative chemotherapy to delay planned irradiation. Results: The median age at diagnosis was 2.6 years. Six patients completed planned chemotherapy without progressive disease and underwent irradiation at completion of chemotherapy. Twenty-three children experienced disease progression during chemotherapy and underwent irradiation at the time of progression. The 5-year overall survival rate for the entire cohort was 51{\%} ± 10{\%}. The 5-year progression-free survival rate was 21{\%} ± 8{\%}. M stage did not impact survival. All patients lost cognitive function during and after therapy at a rate of -3.9 intelligence quotient points per year (P = .0028). Sensory functions declined significantly after therapy (P = .007). All long- term survivors required hormone replacement therapy and had growth abnormalities. Conclusion: The majority of infants treated for medullablastoma experienced disease progression during initial chemotherapy. However, more than half of these patients can be cured with salvage radiation therapy, regardless of M stage. The presence of metastatic disease did not increase the risk of dying from medullablastoma. All patients treated in this fashion have significant neuropsychologic deficits. Our experience demonstrates that medulloblastoma in infancy is a curable disease, albeit at a significant cost.",
author = "Walter, {Andrew W.} and Mulhern, {Raymond K.} and Amar Gajjar and Heideman, {Richard L.} and David Reardon and Sanford, {R. Alex} and Xiaoping Xiong and Kun, {Larry E.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1200/JCO.1999.17.12.3720",
language = "English (US)",
volume = "17",
pages = "3720--3728",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

TY - JOUR

T1 - Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital

AU - Walter, Andrew W.

AU - Mulhern, Raymond K.

AU - Gajjar, Amar

AU - Heideman, Richard L.

AU - Reardon, David

AU - Sanford, R. Alex

AU - Xiong, Xiaoping

AU - Kun, Larry E.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Purpose: Young children treated for medulloblastoma are at especially high risk for morbidity and mortality from their disease and therapy. This study sought to assess the relationship, if any, between patient outcome and M stage. Neuropsychologic and endocrine outcomes were also assessed. Patients and Methods: Twenty-nine consecutively diagnosed infants and young children were treated for medulloblastoma at St Jude Children's Research Hospital between November 1984 and December 1995. All patients were treated with the intent of using postoperative chemotherapy to delay planned irradiation. Results: The median age at diagnosis was 2.6 years. Six patients completed planned chemotherapy without progressive disease and underwent irradiation at completion of chemotherapy. Twenty-three children experienced disease progression during chemotherapy and underwent irradiation at the time of progression. The 5-year overall survival rate for the entire cohort was 51% ± 10%. The 5-year progression-free survival rate was 21% ± 8%. M stage did not impact survival. All patients lost cognitive function during and after therapy at a rate of -3.9 intelligence quotient points per year (P = .0028). Sensory functions declined significantly after therapy (P = .007). All long- term survivors required hormone replacement therapy and had growth abnormalities. Conclusion: The majority of infants treated for medullablastoma experienced disease progression during initial chemotherapy. However, more than half of these patients can be cured with salvage radiation therapy, regardless of M stage. The presence of metastatic disease did not increase the risk of dying from medullablastoma. All patients treated in this fashion have significant neuropsychologic deficits. Our experience demonstrates that medulloblastoma in infancy is a curable disease, albeit at a significant cost.

AB - Purpose: Young children treated for medulloblastoma are at especially high risk for morbidity and mortality from their disease and therapy. This study sought to assess the relationship, if any, between patient outcome and M stage. Neuropsychologic and endocrine outcomes were also assessed. Patients and Methods: Twenty-nine consecutively diagnosed infants and young children were treated for medulloblastoma at St Jude Children's Research Hospital between November 1984 and December 1995. All patients were treated with the intent of using postoperative chemotherapy to delay planned irradiation. Results: The median age at diagnosis was 2.6 years. Six patients completed planned chemotherapy without progressive disease and underwent irradiation at completion of chemotherapy. Twenty-three children experienced disease progression during chemotherapy and underwent irradiation at the time of progression. The 5-year overall survival rate for the entire cohort was 51% ± 10%. The 5-year progression-free survival rate was 21% ± 8%. M stage did not impact survival. All patients lost cognitive function during and after therapy at a rate of -3.9 intelligence quotient points per year (P = .0028). Sensory functions declined significantly after therapy (P = .007). All long- term survivors required hormone replacement therapy and had growth abnormalities. Conclusion: The majority of infants treated for medullablastoma experienced disease progression during initial chemotherapy. However, more than half of these patients can be cured with salvage radiation therapy, regardless of M stage. The presence of metastatic disease did not increase the risk of dying from medullablastoma. All patients treated in this fashion have significant neuropsychologic deficits. Our experience demonstrates that medulloblastoma in infancy is a curable disease, albeit at a significant cost.

UR - http://www.scopus.com/inward/record.url?scp=0032804331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032804331&partnerID=8YFLogxK

U2 - 10.1200/JCO.1999.17.12.3720

DO - 10.1200/JCO.1999.17.12.3720

M3 - Article

C2 - 10577843

AN - SCOPUS:0032804331

VL - 17

SP - 3720

EP - 3728

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -